New techniques in irradiation: clinical implications of perioperative high-dose rate brachytherapy

Martı́nez-Monge, Rafael; Cambeiro, Mauricio

doi:10.1093/annonc/mdi708

Cited by 4 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mart í nez-Monge have reported that 4years' local control rate was 82. 5% for 183 patients with malignant tumor, including 23 cases of gynecologic malignant tumors (Martinez-Monge and Cambeiro, 2005). After implantation, gamma radiation can effectively guarantee the effect by precise radiotherapy.…”

Section: Adverse Reactionsmentioning

confidence: 99%

Efficacy of Permanent Iodine-125 Seed Implants and Gemcitabine Chemotherapy in Patients with Platinum-Resistant Recurrent Ovarian Carcinoma

Yang

Liu²,

Xu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The aim of this study was to explore the efficacy and adverse reactions of CT-guided radioactive 125I-seed implantation treatment combined with chemotherapy for platinum-resistant recurrent ovarian carcinoma. Materials and Methods: From September 2010 to December 2012, 23 patients with platinum-resistant recurrent ovarian carcinoma were enrolled. All the patients refused, could not bear, or were not suitable for surgery. They all had no more than 3 lesions, which were detected and could also be measured by CT. All were clarified as single-lesion or multiple-lesion groups. A total of 41 lesions underwent implantation of from 8 to 106 125I seeds (median=43). Multi-plane implanting was adopted and 125I-seeds of (0.4-0.7)mCi were placed at intervals of (0.5-1.0) cm. After implantation treatment, all patients underwent 4 cycles of chemotherapy with gemcitabine 800 mg/m2 (days 1, 8 and 15). Results: The outcome was evaluated with CT 3 weeks and every 3 months after implantation treatment. After 6 months, the volume of 32 out of 41 lesions (78.0%) was reduced at least 30%, within which 9 lesions completely disappeared(22.0%). Complete response was observed in 7 cases (30.4%), with a partial response in 4 cases (17.4%),4 cases stable(17.4%)and 8 cases showing progression (34.8%). The total clinical remission rate was 47.8% (11/23). The clinical remission rate was 77.8% (7/9) in the single-lesion group and 28.6% (4/14) in the multiple-lesion group with a significant difference between the two(P=0.036). The common side effects observed were mild gastrointestinal reactions. Conclusions: 125I-seed implantation combined with chemotherapy applies an effective way in the treatment of platinum-resistant recurrent ovarian epithelial carcinoma with the advantages of high local control rates, good short-term effects, little trauma and less side effects.

show abstract

Section: Adverse Reactionsmentioning

confidence: 99%

Efficacy of Permanent Iodine-125 Seed Implants and Gemcitabine Chemotherapy in Patients with Platinum-Resistant Recurrent Ovarian Carcinoma

Yang

Liu²,

Xu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The implantation procedure and the general guidelines of the target definition process for each disease site and for several specific clinical situations have been previously described (3). Briefly, the surgical and the radiation oncology teams used the preoperative physical examination and imaging, surgical findings, frozen sections where necessary, and gross examination of the surgical specimen to jointly determine the area to be implanted.…”

Section: Phdrb Techniquementioning

confidence: 99%

“…Perioperative high-dose-rate brachytherapy is, in essence, an accelerated hypofractionated treatment regimen with daily doses ranging from 5 to 10 Gy (1)(2)(3)(4).…”

Section: Introductionmentioning

confidence: 99%

Interaction of 2-Gy Equivalent Dose and Margin Status in Perioperative High-Dose-Rate Brachytherapy

Martı́nez-Monge

Cambeiro

Moreno

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Perioperative high dose rate brachytherapy (PHDRB) is a technique which involves intraoperative insertions of brachytherapy catheters in the tumor bed at time of surgical resection followed by a fractionated brachytherapy treatment in the perioperative period. 2 It combines the advantages of a highly conformal radiation dose delivery with a clear visualization and demarcation of the tumor bed at the time of surgical dissection. This coupled with incorporation of CT-based treatment planning gives it a high level of treatment delivery precision.…”

Section: Introductionmentioning

confidence: 99%

Perioperative high dose rate brachytherapy in head and neck cancers: case report and review of clinical application

et al. 2021

View full text Add to dashboard Cite

show abstract

New techniques in irradiation: clinical implications of perioperative high-dose rate brachytherapy

Cited by 4 publications

References 21 publications

Efficacy of Permanent Iodine-125 Seed Implants and Gemcitabine Chemotherapy in Patients with Platinum-Resistant Recurrent Ovarian Carcinoma

Efficacy of Permanent Iodine-125 Seed Implants and Gemcitabine Chemotherapy in Patients with Platinum-Resistant Recurrent Ovarian Carcinoma

Interaction of 2-Gy Equivalent Dose and Margin Status in Perioperative High-Dose-Rate Brachytherapy

Perioperative high dose rate brachytherapy in head and neck cancers: case report and review of clinical application

Contact Info

Product

Resources

About